

Innovative Medicines Initiative

U-BIOPRED study: Open innovation and severe asthma

Krzysztof Łoboda Jagiellonian University JU Medical College, Kraków, Poland

Innovation vs. invention distiction



- Invention refers more directly to the <u>creation</u> of the idea or method itself
- Innovation [from Latin *innovare*: 'to renew or change']: the use of a better and novel idea or method
- Successful innovation is usually coupled with marketing

Example: Edison's bulb -> compact fluorescent (CFL) bulb -> light-emitting diode (LED) bulb





Innovation in companies and academic institutions



Universities specialise in **research** which may lead to **inventions** and discovery of new research methods, but they are not interested in production

Due to shareholders' expectations, **companies** are mostly interested in **innovative products/methods of commercial value** that might be marketed

Bottleneck: research <-> marketing









Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes



The project addresses the current inability of pre-clinical studies to predict clinical efficacy, which is a major bottleneck in drug development for severe asthma.









- Identify better tools and markers to develop new therapies and diagnostics for severe asthma
- Introduce tools for predicting the effectiveness of future treatments
- Assist in producing new drugs
- Develop a personalised approach to therapy
- Include patients as partners in research









- Clinical data from a large cohort
- Omics technology (genomics, transcriptomics, proteomics, lipidomics)
- Animal and laboratory models
- Human challenge models
- Systems biology







The consortium encompasses the representatives of all stakeholder groups by involving partners from academia (20), biopharma industry (EFPIA) (9), patients/care organisations (6), SMEs (3) and Multinational industry (1)

- Duration: 60 months, started 1 Oct 2009
- Total costs: 22 846 864 €
- **IMI contribution:** 8 977 151 €



EFPIA contribution: 11 007 989 €



Partners









Partners









Our aim




Lipidomics of induced sputum – samples of lower airways excretions

material: induced sputum collected from well defined asthmatic patients and controls (n=725)

methods: high performance liquid chromatography – tandem mass spectrometry

measured analytes: 10 key lipid mediators and their metabolites reflecting cyclooxygenases and lipoxygenases inflammatory pathways









Patient/study subject recruitment









RECRUITMENT (WP3) Preliminary results as of Oct. 5th, 2012

	I		Extra pts					Total			Bronch.		Exacerb.			CTscan	
	Planned		proposed					outstanding		Bronch	Visits	Exacerb.	Visits		CTscan	Total-	
	patients		iп	Total				(planned -	unusable	. Visits	Total -	Visits	Total-	CTscan	Total-	expect	
	per		Barcelon	planned		Actual	Increas	actual -	(SF/DO/viol	Total -	increase	Total -	Increase	Total -	Increase	ed	Amend.
Adult	protocol	Pts in CIA	а	pts	Missing	total	e Actual	unusable)	ators)	Actual	actual	Actual	actual	Actual	actual	(CIA)	approval status
Cohort A	400	378	11	389	11	263	10	155	18	52	3	10	O	78	1		
Cohort B	125	124	-1	123	2	33	3	93	1	3	O	٥	O	10	O		10/15
Cohort C	100	100	12	112	-12	75	٥	42	17	14	O	٥	O	10	1		4/15
Cohort D	100	100	5	105	-5	97	٥	15	12	39	3	٥	O	14	o		1/15
TOTAL	725			729		468	13	305		108	6	10	0	112	2	236	







Preliminary results of the Polish Team

Poland	(07)											
Cohort A	11	3	14	17	17	0	-3				EC meeting 28	Recruited 3 pts more than target. Local CRA supported site to prepare docs for the
Cohort B	4	-3	1	1	1	0	0				Sept	amendment.Submission will be performed on week 38. Recruitment: Investigators are willing to
Cohort C	4	1	5	5	5	0	0					recruit more patients but because of holidays it will be possible at the end of September or even in
	_	_	_	_	_	_	_					October. Difficult to specify how many patients can be included more.
Cohort D	5	0	5	5	5	0	0					
			25	28	28	0	-3					





25th September, 2012, Gdańsk, Poland



Sachs-Olsen C, Sanak M, Lang AM, Gielicz A, Mowinckel P, Lodrup Carlsen KC, Carlsen K-H, Szczeklik A. Eoxins: a new inflammatory pathway in childhood asthma. J Allergy Clin Immunol 2010: 126: 859-867.

Sanak M, Gielicz A, Nagraba K, Kaszuba M, Kumik J, Szczeklik J. Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. Journal of Chromatography B. 2010; 878: 1796-1800.

Sanak M, Gielicz A, Bochenek G, Kaszuba M, Niżankowska-Mogilnicka E, Szczeklik A. Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol 2011; 127: 1141-1147.










Preliminary results of the Polish Team (WP7) – mediators/ hierarchical clustering









Challenges faced during other projects

- Funding for R&D
- European projects: require that project results are widely available free of charge
- Paradox: patents required as project indicators but products/results may not be commercialised









Challenges faced during U-BIOPRED

- Withdrawal of partner from consortium
- Unknown research framework
- Partner cooperation (formal and scientific)
- Recruitment of subjects (loss of data / enrolled subjects)
- Co-financing





Advantages



- + IMI consortium is an optimum research
- framework (innovation is possible!)
- + We are already close to our aim 1: Identify better tools and markers to develop new therapies and diagnostics for severe asthma
- + Involvement in new state-of-the-art research
- + Funding for R&D
- + Local capacity/team building
- + Prestige / "good CV line" for future innovative projects









Thank you

Questions? krzysztof.loboda@uj.edu.pl



